Kura Oncology CEO Troy Edward Buys 49,900 Shares in Two Transactions.

Kura Oncology, Inc. (KURA) has disclosed that Director, President and CEO Wilson Troy Edward has made two recent share purchases. On August 12, 2025, Edward acquired 36,506 shares at a price of $5.85 per share. Two days later, on August 13, 2025, Edward purchased an additional 13,494 shares at a price of $6.64 per share.

Kura Oncology, Inc. (KURA) has disclosed that its Director, President, and CEO, Troy Edward Wilson, has made two recent share purchases. On August 12, 2025, Wilson acquired 36,506 shares at a price of $5.85 per share. Two days later, on August 13, 2025, he purchased an additional 13,494 shares at a price of $6.64 per share [1].

Following these transactions, Wilson directly owns 50,968 shares and indirectly owns 579,194 shares through the One Fish Two Fish Revocable Trust and the Lorax Charitable Remainder Unitrust [1].

The total purchase amount was $303,201, with transactions executed at weighted average prices of $5.8505 and $6.6417 respectively [1].

These purchases come at a time when Kura Oncology is facing financial challenges. The company reported a substantial shortfall in revenue expectations for the second quarter of 2025, posting actual revenue of $15.3 million, significantly below the forecasted $39.1 million. The earnings per share (EPS) were also lower than anticipated, with a reported loss of $0.75 compared to the expected loss of $0.41 [2].

Despite these challenges, JMP Securities has maintained a "Market Outperform" rating for Kura Oncology, lowering its price target from $28 to $24. The analyst's decision is based on an updated analysis of the company's clinical-stage biopharmaceutical pipeline, which targets cancer signaling pathways. The firm also cited Kura's strong cash position of $630.7 million, which is expected to fully fund its planned front-line trials scheduled to begin in the second half of 2025 [3].

Investors are likely to keep a close watch on any further developments from Kura Oncology, as the recent earnings report highlights the company's current financial performance.

References:
[1] https://www.tradingview.com/news/tradingview:8e770a9f9c27a:0-kura-oncology-ceo-troy-edward-wilson-buys-50-000-shares/
[2] https://www.stocktitan.net/sec-filings/KURA/form-4-kura-oncology-inc-insider-trading-activity-2f8d202f7a7a.html
[3] https://www.ainvest.com/news/jmp-securities-lowers-kura-oncology-price-target-24-maintains-market-outperform-rating-2508/